Danielle M Brander
7PUBLICATIONS
41CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Dec 31, 2025
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.Danielle M Brander, Andrew W Roberts, Thomas J Kipps
|Dec 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.Matthew S Davids, Danielle M Brander, Yesid Alvarado-Valero
|Dec 12, 2024
Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia.Akash Roy, Danielle M Brander, Elizabeth G Hill
|Dec 08, 2024
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.Mazyar Shadman, Talha Munir, Tadeusz Robak
|Nov 05, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.Toby A Eyre, Lindsey E Roeker, Christopher P Fox
|May 03, 2019
Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al.J Brice Weinberg, Danielle M Brander, Dale J Christensen
Pageof 2
Frequent Collaborators
2 joint publications
Daphne R Friedman
1 joint publications
Mazyar Shadman
1 joint publications
Tadeusz Robak
1 joint publications
Jennifer R Brown
1 joint publications
Brad S Kahl
1 joint publications
Paolo Ghia
1 joint publications
Krzysztof Giannopoulos
1 joint publications
Martin Šimkovič
1 joint publications
Stephen S Opat
1 joint publications
Richard Greil
